Sarepta will rebound strongly from eteplirsen US delay, says analyst
US rare and infectious disease specialist Sarepta Therapeutics (Nasdaq: SRPT) remains a strong contender in the Duchenne muscular dystrophy (DMD) treatment market, despite a delay in the development of its novel, exon-skipping drug eteplirsen from the end of this year, says an analyst.
According to Nikhilesh Sanyal, research and consulting firm GlobalData's analyst covering immunology, the US Food and Drug Administration’s call for additional data in eteplirsen’s New Drug Application appears to be a detrimental setback for Sarepta in the race to develop the first disease-modifying therapy for DMD (The Pharma Letters October 28 and 31).
However, the analyst believes that the company can address the issue by mid-2015, with the drug expected to treat approximately 13% of DMD patients in the US.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze